Depomed changes name to Assertio Therapeutics

 Depomed changes name to Assertio Therapeutics

Depomed changes name to Assertio Therapeutics

Shots:
  • Depomed changes name to Assertio Therapeutics on Aug 15, 2018, with a strategic focus on our neurology, orphan and specialty medicines
  • The rebranding is done after Senate committee opened probe for opioid marketing last year
  • Assertio’s common stock has started trading with new ticker “ASRT” from Aug 15, 2018. Depomed also completed the relocation of headquarters from Newark to Lake Forest
Click here to read full press release/ article | Ref: Assertio Therapeutics| Image:  Smarteranalyst

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post